Daxor logo thumbnail.png
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
January 19, 2023 08:00 ET | Daxor Corporation
Oak Ridge, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of...
chf.jpg
CHF Solutions Initiatives at HFSA 24th Annual Scientific Meeting Highlight Aquadex Therapy Performance in Heart Failure
September 30, 2020 08:00 ET | CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
September 06, 2019 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two poster presentations at the 23rd Annual Heart Failure Society of America...
54741_Image_jpeg.jpg
Daxor Corporation to Exhibit at the 22nd Annual Scientific Meeting of the Heart Failure Society of America
September 12, 2018 08:30 ET | Daxor Corporation
NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting
September 18, 2017 07:30 ET | Cytokinetics, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin...
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
September 29, 2015 21:10 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for...